79. Homozygous familial hypercholesterolemia Clinical trials / Disease details
Clinical trials : 142 / Drugs : 114 - (DrugBank : 29) / Drug target genes : 9 - Drug target pathways : 18
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04948008 (ClinicalTrials.gov) | November 5, 2019 | 29/6/2021 | Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia | A Seamless Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia in China | Familial Hypercholesterolemia - Homozygous;Lipid Metabolism Disorders;Proprotein Convertase Subtilisin/Kexin 9 | Biological: IBI306 | Shenzhen People's Hospital | NULL | Recruiting | 18 Years | 80 Years | All | 8 | Phase 2/Phase 3 | China |
| 2 | NCT04031742 (ClinicalTrials.gov) | September 29, 2019 | 22/7/2019 | A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia | Phase 2b/3 Study to Assess the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia. Part 1 - Open-label, Two-arm, Multicenter Pilot Study to Evaluate Efficacy and Safety of IBI 306 in Subjects With Homozygous Familial Hypercholesterolemia. Part 2 - Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of IBI 306 in Subjects With Homozygous Familial Hypercholesterolemia | Homozygous Familial Hypercholesterolemia | Biological: IBI306 | Innovent Biologics (Suzhou) Co. Ltd. | NULL | Recruiting | 18 Years | 80 Years | All | 30 | Phase 2/Phase 3 | China |